Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression - Forbes
Links shared publicly online about this topic.
- 26total visits
Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression - Forbes
AstraZeneca announced today that its lipid-lowering agent rosuvastatin (Crestor) was not superior to atorvastatin (Lipitor, Pfizer) in reducing the progression of atherosclerosis as assessed by IVUS. The company announced the top-line results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN), which is scheduled to be [...]
View full resource at forbes.com
Tags: Heart Disease, Circulatory Disorders, Atherosclerosis, Cholesterol Medication, Drug, Lipitor, Crestor, AstraZeneca
Most Recently Shared on September 2, 2011 at 11:25 pm By:
Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression: AstraZeneca annou... http://t.co/c0y6V2E #drug
Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression « CardioBrief
cardiobrief.org — “Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression « CardioBrief” View full resource at cardiobrief.org
Most Recently Shared on September 2, 2011 at 8:53 pm By:
James Rudd Internist, Cardiologist, Physician, and Doctor
Rosuvastatin Fails to Best Atorvastatin in IVUS Study of Atherosclerosis Progression http://j.mp/qotYC5
Advertisement
